| Methods |
Double‐blind, placebo‐controlled, cross‐over RCT running for 28 weeks. |
| Participants |
Country: Denmark Setting: single centre Inclusion criteria: patients with type 2 DM (WHO criteria); HbA1c ≥ 48 mmol/mol (6.5%); persistent albuminuria (≥ 30 mg/g creatinine (3.39 mg/mmol) in at least 2 out of 3 consecutive morning spot urine samples) and who were receiving stable RAS‐blocking treatment Number (randomised/completed): 32/27 Mean age ± SD: 65 ± 7 years Sex (M/F): 22/5 Exclusion criteria: diagnosis of clinical heart failure; eGFR ≤ 30 mL/min/1.73 m2 |
| Interventions |
Treatment group
Liraglutide Standard therapy
Control group
After 12 weeks of treatment, patients underwent a 4‐week washout period prior to crossing over to the other treatment group for 12 weeks. Participants attended a baseline examination visit and were instructed in SC injection of the study drug. Participants were treated with liraglutide/placebo 0.6 mg/d for 7 days, escalated to 1.2 mg/d for 7 days and lastly to 1.8 mg/d for the remaining 10 weeks or matching placebo |
| Outcomes |
Change in UAER after 12 weeks of liraglutide treatment compared with placebo treatment The effect of liraglutide treatment on measured GFR (51Cr‐EDTA) and RAS hormones in plasma (renin, renin activity, angiotensin II and aldosterone) 24‐hour SBP, 24‐hour DBP, 24‐hour heart rate and fractional albumin clearance |
| Notes |
Written to authors for the subgroup analysis for those patients with an eGFR < 60. There were 11 patients with an eGFR < 60. We are awaiting reply from authors for the sub‐analysis |
